Fire accident at Parmax Pharma’s plant

There has been no loss or injury to human life

Sanofi completes closing for potential first-in-class vaccine against ExPEC

Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis

EnginZyme produces key mRNA vaccine ingredient using biocatalysis

2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines

Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19

The companies plan to start a pivotal Phase 3 trial in the coming months

FDA approves only vaccine Penbraya for treatment of meningococcal disease in adolescents

The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease

IMI 5.0 campaign with special focus on improvement of Measles and Rubella vaccination coverage

Over 34 lakh children and 6 lakh pregnant women were administered vaccine doses during the first 2 rounds of IMI 5.0 campaign across the country

Nobel prize 2023 for medicine awarded to Katalin Karikó, Drew Weissman for research on mRNA vaccines to fight Covid-19

The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19

BioNTech and CEPI partnership to advance mRNA Mpox Vaccine development

The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases

CureVac highlights shift to mRNA technology in seasonal influenza vaccine development: GlobalData

CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology

Takara Bio Europe launches high-quality enzymes suitable for pre-clinical mRNA vaccine